Skip to main content
. 2021 Dec 16;21(2):100187. doi: 10.1016/j.mcpro.2021.100187

Fig. 7.

Fig. 7

IDH2 enhanced the sensitivity to ADR and IMA in K562 cells.A and C, the parental-sensitive and IMA-resistant K562 cells were treated with various concentrations (4, 2, 1, 0.5, … 0 μM) of IMA alone or combined with 4 μM or 2 μM AGI-6780 for 48 h. B and D, the parental-sensitive and ADR-resistant K562 cells were treated with various concentrations (4, 2, 1, 0.5, … 0 μM) of ADR alone or combined with 4 μM or 2 μM AGI-6780 for 48 h. The cell survival rate was calculated and plotted in each group. The downward shift of the survival curves indicated suppressed proliferation. Columns are expressed as mean ± SD. E–H, surface plots show the synergistic or antagonistic effects from the combination of two drugs. The parental K562 treated with AGI-6780 (0, 2, and 4 μM) combined with IMA (0–4 μM) (E) or ADR (0–4 μM) (F). G, the IMA resistance model cell treated with AGI-6780 (0, 2, and 4 μM) combined with IMA (0–4 μM). H, the ADR resistance model cell treated with AGI-6780 (0, 2, and 4 μM) combined with ADR (0–4 μM). Each point represents the mean of two independent cytotoxicity assay results. Plots were generated using Combenefit by applying the Bliss independence model. ADR, adriamycin; IDH2, isocitrate dehydrogenase (NADP(+)) 2; IMA, imatinib.